Company intelligence / Profile preview

Advantage Therapy

Miami, Florida, United States

Ownership: Private
Development stage: Other

Overview

ADvantage Therapeutics is a clinical-stage biotech focused on neurodegenerative and aging-related diseases, with a lead candidate (AD04™) in Phase 2b trials for Alzheimer’s disease. The company is also developing mRNA-based therapies to boost Klotho protein levels, which may address a broad range of age-related conditions. Preliminary trial results for AD04™ suggest slower cognitive decline and less hippocampal atrophy compared to controls, though these results require further validation.

Therapeutic areas: NephrologyEndocrinologyNeurologyMetabolic DisordersOtherOncology
Modalities: mRNA-based drugProteinSmall moleculeSubcutaneous injectable
Industry: Biotech

Partnerships

Longevitytech.fund (lead investor in Klothea Bio)

Beyond the preview

Go deeper on Advantage Therapy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advantage Therapy.

Explore the full profile